RobertMWenhamMDMS FACS FACOG

Gynecologic Cancer

Chair and Director of Research, Gynecologic Oncology at Moffitt Cancer Center

Overview of Dr. Wenham

Dr. Robert Wenham is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 20 years. Dr. Wenham accepts several types of health insurance, listed below. He is one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(607) 400-7263

Education & Training

Duke University HospitalFellowship, Gynecologic Oncology, 2004
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolInternship, Obstetrics and Gynecology, 1997 - 2001
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Obstetrics and Gynecology, 2001
University of Texas Southwestern Medical SchoolClass of 1997

Certifications & Licensure

FL State Medical License 2004 - 2025
NC State Medical License 2001 - 2014
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors Start of enrollment: 2006 Mar 01
Completed
Phase 1
Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 1
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Quality of Life in Patients Undergoing Total Pelvic Exenteration Start of enrollment: 2005 Jan 01
Active, not recruiting
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan Start of enrollment: 2008 Jul 01
Terminated
Not Applicable
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids Start of enrollment: 2011 Jun 13
Completed
Phase 1
Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer Start of enrollment: 2010 Jan 01
Completed
Not Applicable
PTX-200 and Carboplatin in Ovarian Cancer Start of enrollment: 2014 Sep 01
Terminated
Phase 1, Phase 2
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 3
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer Start of enrollment: 2015 Oct 20
Completed
Phase 2
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy Start of enrollment: 2019 Mar 14
Terminated
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

Post-traumatic reactions and quality of life after pelvic exenteration for gynecologic cancer: a retrospective cohort study.
Lora M A Thompson, Nele Loecher, Alexandra Albizu-Jacob, Hye Sook Chon, Robert M Wenham
Supportive Care in Cancer. 2024-10-15
Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
Aditi Gupta, Roisin E O'Cearbhaill, Matthew S Block, Erika Hamilton, Jason A Konner
Gynecologic Oncology. 2024-10-01
1 citations
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receivi...
Joyce F Liu, Niya Xiong, Robert M Wenham, Andrea Wahner-Hendrickson, Deborah K Armstrong
Gynecologic Oncology. 2024-08-01

Lectures

Moffitt Cancer Center Womens Cancers Western Caribbean Cruise
Continuing Education, Inc., Tampa, Florida - 11/27/2011

Press Mentions

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical TrialOctober 15th, 2024
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T TrialSeptember 30th, 2024
‘Our Hero’: 2-Year-Old Georgia Girl Diagnosed with Rare Ovarian CancerMarch 10th, 2019
Join now to see all

Professional Memberships

American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment